Vivos Therapeutics Inc (NASDAQ: VVOS)’s stock price has gone rise by 14.81 in comparison to its previous close of 2.16, however, the company has experienced a 11.71% increase in its stock price over the last five trading days. seekingalpha.com reported 2025-05-15 that Vivos Therapeutics, Inc. (NASDAQ:VVOS ) Q1 2025 Earnings Conference Call May 15, 2025 5:00 PM ET Company Participants Brad Amman – CFO Kirk Huntsman – Chairman and CEO Conference Call Participants Do Kim – Water Tower Research Lucas Ward – Ascendiant Capital Markets Operator Good day, everyone. And welcome to the Vivos Therapeutics First Quarter 2025 Earnings Call.
Is It Worth Investing in Vivos Therapeutics Inc (NASDAQ: VVOS) Right Now?
The stock has a 36-month beta value of 6.98. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for VVOS is 4.59M, and at present, short sellers hold a 6.66% of that float. On June 19, 2025, the average trading volume of VVOS was 102.10K shares.
VVOS’s Market Performance
VVOS’s stock has seen a 11.71% increase for the week, with a 7.36% rise in the past month and a -29.75% fall in the past quarter. The volatility ratio for the week is 7.31%, and the volatility levels for the past 30 days are at 4.98% for Vivos Therapeutics Inc The simple moving average for the past 20 days is 10.05% for VVOS’s stock, with a -23.19% simple moving average for the past 200 days.
VVOS Trading at 1.54% from the 50-Day Moving Average
After a stumble in the market that brought VVOS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -60.51% of loss for the given period.
Stock Fundamentals for VVOS
Current profitability levels for the company are sitting at:
- -0.76 for the present operating margin
- 0.59 for the gross margin
The net margin for Vivos Therapeutics Inc stands at -0.77. The total capital return value is set at -1.69. Equity return is now at value -450.47, with -97.35 for asset returns.
Based on Vivos Therapeutics Inc (VVOS), the company’s capital structure generated 0.24 points at debt to capital in total, while cash flow to debt ratio is standing at -9.99.
Currently, EBITDA for the company is -10.55 million with net debt to EBITDA at 0.09. When we switch over and look at the enterprise to sales, we see a ratio of 0.93. The receivables turnover for the company is 20.37for trailing twelve months and the total asset turnover is 1.3. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.77.
Conclusion
To sum up, Vivos Therapeutics Inc (VVOS) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
